Miastenia gravis: las nueva terapias dan mejoría sostenida
Myasthenia gravis: Newer therapies offer sustained improvement.
YUEBING LI, MD, PhD, YEESHU ARORA, MD, KERRY LEVIN, MD
CLEVELAND CLINIC JOURNAL OF MEDICINE VOLUME 80 * NUMBER 11 NOVEMBER 2013
Myasthenia gravis is a prototypical antibody-mediated autoimmune neuromuscular disorder. Treatments have improved over the past 30 years, leading to significantly fewer deaths and better quality of life. Future research should further elucidate its pathogenesis, reveal better ways to diagnose it, and yield new treatments.
http://www.ccjm.org/content/80/11/711.full.pdf
Atentamente
Anestesiología y Medicina del Dolor
www.anestesia-dolor.org
Myasthenia gravis: Newer therapies offer sustained improvement.
YUEBING LI, MD, PhD, YEESHU ARORA, MD, KERRY LEVIN, MD
CLEVELAND CLINIC JOURNAL OF MEDICINE VOLUME 80 * NUMBER 11 NOVEMBER 2013
Myasthenia gravis is a prototypical antibody-mediated autoimmune neuromuscular disorder. Treatments have improved over the past 30 years, leading to significantly fewer deaths and better quality of life. Future research should further elucidate its pathogenesis, reveal better ways to diagnose it, and yield new treatments.
http://www.ccjm.org/content/80/11/711.full.pdf
Atentamente
Anestesiología y Medicina del Dolor
www.anestesia-dolor.org
No hay comentarios:
Publicar un comentario